Sinmary In a study of 29 patients who were receiving or had received interferon b (IFN-b) 
Among patients who were receiving the cytokine. four had progressive disease, one was in complete remission and one in partial remission. Neutralising activity was also detected to natural human leucocyte IFN--a Interferons are a heterogeneous family of proteins which have pleiotropic biological effects in addition to their specific antiviral activity. The availability of highly purified human leucocyte interferon (IFN-x) and the development of recombinant products has made it possible to explore the potential therapeutic benefits of these molecules in the treatment of cancer (Mellstedt et al., 1979; Gutterman et al., 1980) .
In untreated patients with multiple myeloma, IFN-a used as a single agent has been shown to achieve a response rate of 20-30% (Ahre et al., 1984) . Similar response rates have been achieved in patients with advanced multiple myeloma refractory to cytotoxic chemotherapy or in relapse (Costanzi et al., 1985; Rodjer et al., 1990) . Addition of IFN-x to conventional induction therapy has increased progressionfree survival (IFN-a2b: Ludwig et al., 1991; Westin et al., 1991) and response frequency (natural IFN-a: Mellstedt et al.. 1991 : Osterborg et al.. 1993 in previously untreated patients. However, in a small non-randomised study there was no significant difference in survival duration between patients given conventional chemotherapy with or without natural leucocyte IFN (Umeda et al., 1991) .
Recent studies have concentrated on the use of IFN-zs as maintenance therapy for multiple myeloma. Intensification of maintenance therapy with glucocorticoids and IFN-a2b following conventional chemotherapy induced a further reduction of the M component in 50% of patients who responded to chemotherapy (Palumbo et al., 1992) . Among 41 patients who failed to achieve remission with chemotherapy, 32% achieved at least a partial response with IFN/dexamethasone, and 42% who had responded to induction showed a further reduction in tumour burden (Salmon et al., 1991) . In a non-randomised study, the efficacy of maintenance therapy with recombinant IFN-a2b alone was dependent on the response to intensive therapy with high-dose melphalan (HDM) and total body irradiation. Amongst patients who achieved complete remission (CR) the probability of progression-free survival at 33 months was significantly greater than that for patients who achieved partial response (PR) (Attal et al., 1992) . In an ongoing randomised study of 84 patients at the Royal Marsden Hospital, recombinant IFN-eb increased the median progression-free survival following intensive chemotherapy with HDM and autologous bone marrow rescue (ABMR) (Cunningham et al.. 1993 In vitro IFN-a reduced the proliferation of a myeloma cell line at clinically achievable drug concentrations (80-800 U ml-') and acted synergistically with vinblastine and cisplatin (Aapro et al., 1983 Assay for IFN antibodies Serum samples were stored at -20°C and were heat inactivated at 56°C for 30 min before being analysed. They were assayed for anti-IFN-a, antibodies by two different methods.
The presence of binding antibodies to IFN-a2b was measured using a solid-phase enzyme-linked immunoassay (ELISA) (Anawa Labs, Zurich, Switzerland). The assay uses beads coated with recombinant IFN-a2 (rIFN-a2), which were incubated with the serum samples for 24 h at 4C. The anti-IFN-a2 antibodies in the serum were captured by the beads and, after washing, incubated at 40C for 24 h with rIFN-a2-peroxidase conjugate. After washing, the enzyme activity on the beads was measured by incubation with enzyme substrate (tetramethylbenzidine) and measurement of the optical density at 450 nm. Human serum with known amounts of rabbit antibody to rIFN--, was used as a standard for the calibration curve over the range of 0 to 10 (arbitrary) units ml -. The specificity of the signal obtained with patients' sera was checked with the confirmatory test to exclude false-positive results. In the confirmatory test, the signal of antibody-positive sera was depressed by addition of free rIFN-a2, whereas non-specific binding was not suppressed by the addition of free IFN-,.
The IFN neutralisation bioassay is based on inhibition by IFN of viral cytopathic effect (Freund et al., 1989; Ross et al., 1990 titrations were carried out to establish the minimum concentrations of virus that produced the most pronounced change in optical density (OD) and the minimum concentration of IFN-a required to reverse the cytopathic effect at 540 nm. Ninety-six-well microtitre plates were seeded with HeLa cells at a concentration of 10 cells per well in 100 p1 of RPMI-1640 medium supplemented with 7.5% FCS. After attachment for 4 h at 37C, 100 p1 of IFN-a was added to give concentrations between 0.05 and 2.500 units ml-' in maintenance medium (see above). Cultures were incubated overnight. Cocal virus was added in 100 1l of maintenance medium at doses of 0.07. 0.70 and 7.0 p.f.u. per cell and incubation continued for 24 h. The medium was discarded into bleach and I00p1 of MIT (1.25 ngml-') added to each well. After 2 h at 37C. 100 p1 of lysis solution was added to each well and the plate incubated for 45 min before reading at 540 nm in a Titertek multiscanner. The concentration of Cocal virus which gave the optimal change in OD signal was 0.07 p.f.u. per cell. The protective capacity of both human leucocyte IFN-a and IFN-eb against viral cytopathic effect increased between doses of 0.25 and 5.0 units ml-' IFN-a and thereafter remained constant. All tests with patients' sera were done using IFN-a at a concentration of 5 units ml' (i.e. I unit per well). Polyclonal rabbit anti-human leucocyte IFN-<x antibody (r.a-huIFN) was titrated against the optimal concentration of Cocal and 5 units ml' IFN-a to establish the sensitivity of the MIT assay with respect to changes in OD as a function of antibody concentration (Figure 1 ). Also. both natural and recombinant IFN-a were titrated against 5 units ml-' r.a-huIFN to determine the sensitivity of the assay with respect to IFN-x concentration (Figure 2 IFN-a2b at the time of testing were positive for antibody; 11
had PD, two were in PR and two in CR (Table II) . Twentythree samples from 17 patients were negative: nine had PD, six were in PR and two in CR. The median duration of maintenance therapy in both antibody-positive and -negative patients was 12 months (range 5-44 months). Also, there was no significant difference in the distribution of length of treatment with IFN-M2b between antibody-positive and antibody-negative patients.
Among patients who had antibody to IFN-e2b. one patient Table II ). All samples which were positive for antibody in the ELISA were tested for neutralising antibody in the virus growth inhibition assay with both natural human leucocyte IFN-a and IFNa.b. Among patients who were receiving IFN-a2b, neutralising antibody was detected in seven samples from six patients (Table III) . Serum remaining two patients (nos. 14 and 15) had been maintained on IFN-a:b for 11 months since the diagnosis of PD. One patient (no. 15) had received low doses of melphalan at the onset of PD before starting a second course of IFN-a2b. In five samples of serum, the antiviral effect of both natural human leucocyte IFN-a and IFN-a2b was inhibited. In the sixth patient (no. 12), antibody to IFN-a-b was found. but not to natural human leucocyte IFN-a (Table III) . In one patient (no. 9) who had activity against both sources of IFN-a, the antibody titre against natural IFN-z was greater than that against IFN-a,t but antibody to IFN-a:b was not detectable in a sample taken 2 months later. Among patients who were not receiving IFN-a:b. neutralising antibody to natural IFN-a (but not IFN-12b) was detected 1 month after cessation of treatment in one patient (no. 10). In a sample taken 2 months after treatment no antibody was detected to either IFN-a (Table III) . This patient has remained in PR.
To determine the nature of neutralising antibody in patients' serum, goat anti-human IgG or IgM was equilibrated with sera at a dilution of 1:20 from all patients who were positive for neutralising antibody before mixing with IFN-a2b or natural IFN-c. Antibody to human IgG removed anti-IFN activity, whereas antibody to human IgM had no effect.
Because other workers have shown that antibodies to natural human leucocyte IFN-a and IFN-a2b are present in normal donor serum (Ross et al., 1990) , we examined serum samples from six normal donors and one patient before the start of maintenance IFN therapy. In no instance were neutralising antibodies detectable in our assay system.
In one patient (no. 14) for whom serum samples have been available since relapse and who was still receiving IFN-a2b, the neutralising antibody titre to both natural human leucocyte IFN-a and IFN-a2b was 320 after 9 months of maintenance therapy, and this declined to zero as the IFN-ab course continued and the patient received no other treatment (Table IV) . In a second patient (no. 9) who was in CR and had no detectable antibodies in the ELISA in a sample taken after 3 months' IFN-M2b treatment, antibodies were detected in both assays as therapy continued and the patient entered PD, and then began to decline with time (Table V) . At the Royal Marsden Hospital the use of IFN-a2b as maintenance therapy in the treatment of multiple myeloma is increasing because of the encouraging results monitored by the prolongation of remission in patients who achieve CR after intensive therapy with HDM, ABMR. Despite the continuing response of more than 50% of these patients for 4 years, IFN-a,b is not curative. Relapse has occurred in approximately 30% of patients who achieved CR, and there appears to be no significant benefit from IFN-a2b maintenance therapy in patients who exhibit PR.
In other haematological disorders, neutralising antibodies have been temporarily associated with a decrease in response to IFN-a (Figlin & Itri. 1988) , particularly among patients with B-cell disorders (Leavitt et al., 1987; Quesada et al., 1987; von Wussow et al., 1987; Steis et al., 1988) , however neutralising antibodies have had no effect on clinical outcome in some trials Steis et al., 1991) . In chronic myeloid leukaemia (CML) the development of neutralising antibodies was associated with relapse or refractoriness to IFN-a2b (Freund et al., 1989) . In a case report, the evolution of progressive disease in a patient with CML which corresponded to the development of neutralising antibodies to recombinant IFN-a,b was obviated by changing to human leucocyte IFN (Freund et al., 1988) .
The data in this study show that, despite impairment of immune function which is associated with multiple myeloma, 62.5% (15 24) of patients who were receiving IFN-a2b at the time of sampling had antibodies to IFNax, as measured by a solid-phase ELISA. This unexpectedly high number of patients who were antibody positive by ELISA was not confirmed using virus growth inhibition as the end point. Only 7,19 serum samples which were positive by ELISA had neutralising antibody. These samples were from six patients who were receiving IFN-a2b, of whom four were in PD, one in PR and one in CR, equivalent to 16% of the total patient population. Despite an increase in tumour mass and paraprotein in the four patients who had PD, immune function was not abolished since the production of antibody involves a B-cell response to antigen. Additionally, although the number of patients with neutralising antibody was small, there was no indication that patients with myeloma of a particular isotype were more prone to antibody formation.
Not only did the ELISA fail to predict the presence of neutralising antibody, but there was no correlation between the magnitude of the antibody response detected by ELISA and the neutralising titre. We suggest that a primary screen using a solid-phase ELISA is of little benefit in predicting neutralising antibody because of the high number of false positives encountered in this study. Other workers have shown that the ability to detect antibody to IFN-a is dependent on the assay system and on the type of recombinant IFN (Figlin & Itri. 1988; Geysen et al., 1988; Steinmann et al., 1992) . In a study by Spiegel et al. (1986) , using an iodinated radioimmunoassay, a low incidence of antibody was found in patients given IFN-m2,, suggesting that this molecule had weak antigenicity. However, comparison of radioimmunoassay with an enzyme-linked immunoassay suggested that this was probably due to its lower sensitivity (Itnr et al., 1987) . Although neutralising antibody to IFN-a2b was not detected in 1:20 dilution in normal donor serum in this study, the presence of antibody to natural IFN-a., which cross-reacted with recombinant IFN-2,, in serum at the same dilution from 200 normal donors, prompted Ross et al. (1990) to suggest that autoantibodies may be a part of normal immune regulation resulting from exposure to endogenous IFN-a2. Since neutralising antibodies to natural IFN-x were detected in some patients receiving IFN-M2b, it cannot be concluded that they resulted from autoantibody production or because of stimulation of pre-B cells. Since the stimulation of memory B cells should result in an increasing neutralising titre as therapy continues, the observation that neutralising antibody was detected transiently in two patients who remain in remission while receiving IFN-e,b suggests that antibody production does not involve memory B cells in these patients. Furthermore, the failure of these antibodies to affect the response in patients in remission suggests that they have a significantly lower affinity for ligand than that of ligand for its cellular receptor.
Although multiple myeloma is associated with the presence of excess plasma cells in the bone marrow, the plasma cell may not represent the major proliferative compartment. The presence of idiotypic B lymphocytes in the peripheral circulation (Ruiz-Arguelles et al.. 1984) and the observation that clonogenic myeloma cells have lymphoplasmacytoid as well as plasmacytoid morphology in vitro (Millar et al., 1988) suggest that this compartment may consist of progenitor B cells that have undergone gene rearrangement. The apparent failure to evoke a memory B-cell response to IFN-mb in two patients who remain in remission while receiving the cytokine suggests either that once B cells had encountered antigen they failed to be stored as memory B cells or that once stored they were inhibited from responding to further antigenic stimulus.
Owing to the immune suppressive nature of multiple myeloma, it is unlikely that neutralising antibodies to IFN-a2b will persist as the disease progresses because of the increase in the size of the malignant clone concomitant with a decrease in polyclonal immunoglobulin secretion as a result of inhibition of normal B-cell development. This is likely to occur irrespective of whether memory B cells are involved in the antibody response.
In conclusion, although neutralising antibody to IFN-M2b was detected in approximately 16% of patients with multiple myeloma at relapse, it is unlikely that these antibodies were responsible for the decline in response to IFN-2b, since the appearance of neutralising antibody was also found transiently in patients who remain in remission and are continuing to receive the cytokine.
